Walgreens Reinvents Nation’s Largest Health and Wellbeing-centered Loyalty Program with myWalgreens to Offer Customers Many More Benefits
19.11.2020 16:00:00 EET | Business Wire | Press release
Walgreens today announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offering available today*. Customers can now shop online and on a fully-redesigned mobile app for health and wellness items, and then pick them up in the store, curbside or at the drive-thru in as little as 30 minutes.**
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005676/en/
Walgreens pickup at curbside (Photo: Business Wire)
Walgreens has the nation’s largest health and wellbeing-centered customer loyalty program, with more than 100 million members. It’s now easier than ever for its members to stay well, shop conveniently and save money and time seamlessly across more than 9,000 stores, Walgreens.com and the mobile app.
The new benefits are in addition to many others already offered by Walgreens. These include an at-home delivery service through DoorDash and Postmates and a Prescription Savings Club with up to 80 percent off cash retail prices.
myWalgreens members can sign up quickly and easily for no cost, and will now receive:
- One percent Walgreens Cash rewards storewide
- Five percent Walgreens Cash rewards on Walgreens branded products
- “Only for you” exclusive deals
Additionally, the mobile app now features a broad range of health and wellness services for customers and patients, including a 24/7 pharmacy chat, access to find and book medical care and vaccination appointments, personalized health and wellness advice, real-time flu alerts and more. The previous version of the app is already very popular, and has been downloaded more than 65 million times.
“As America’s community pharmacy, Walgreens is delivering an unparalleled experience to help customers and patients manage their health and wellbeing during the most severe health crisis of our lifetimes,” said John Standley, Walgreens president. “As always, our more than 25,000 community pharmacists remain at the core of our offering. Our pharmacists and patient care teams do far more than just filling prescriptions – they provide trusted advice, personalized support and a vast range of services.”
The debut of myWalgreens marks another milestone in the company’s digital transformation. Walgreens delivers customers more and more benefits and a highly-personalized experience by working with the very best technology and customer-insight partners, including Microsoft, Adobe and Epsilon.
Online or on the app, myWalgreens members can:
Save Time and Increase Convenience
- Shop a full assortment of more than 27,000 items, including everyday health and wellness and over-the-counter essentials, as well as photos
- Add a payment method to their digital wallet for faster contactless checkout
- Redeem Walgreens Cash rewards instantly at checkout
- Choose digital receipts for quick contactless checkout and to track purchases
Stay Healthy
- Earn bonus Walgreens Cash rewards for achieving health goals
- Receive daily, personalized recommendations for health and wellness, as well as real-time local environment and health forecasts
Help Communities
- Donate their Walgreens Cash rewards to charity (the eligible charity organizations will rotate, beginning with the Full Plate Project, a program of Comic Relief U.S.’ Red Nose Day which works to end child poverty)
Starting today, current Walgreens Balance Rewards members can transfer their membership to myWalgreens at mywalgreens.com. Current Balance Rewards members have until January 31, 2021 to sign up for myWalgreens to ensure that existing rewards roll over to the new program. Over the next several months, myWalgreens will announce even more benefits for customers and patients.
Click here for myWalgreens press kit, including a logo, images and app screenshots.
About Walgreens
Walgreens (www.walgreens.com) is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), a global leader in retail and wholesale pharmacy. As America’s most loved pharmacy, health and beauty company, Walgreens purpose is to champion the health and wellbeing of every community in America. Operating more than 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving approximately 8 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with platforms bringing together physical and digital, supported by the latest technology to deliver high-quality products and services in local communities nationwide.
* As compared to national omni-channel food and pharmacy mass retailers that offer store pick-up free-of-charge.
** For Walgreens store locations that are not open 24 hours, orders must be placed at least one hour prior to store closing in order to be eligible. Otherwise, order will be ready the following business day. Customer will be notified via email when order is ready for pickup and will be provided instructions for a drive-up experience that complies with social distancing guidelines. Orders are not guaranteed to be ready within the 30-minute time window and may be subject to change or substitution depending on product availability at the time order is placed. Orders with age-restricted items may only be picked up in store. Prescription orders not eligible but may be ordered through Walgreens Express®. To find the location and hours of a Walgreens store near you, visit Walgreens.com/FindAStore.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005676/en/
Contact information
Walgreens PR Contact:
Emily Hartwig-Mekstan
emily.hartwig@walgreens.com
Walgreens Boots Alliance PR Contact:
Morry Smulevitz
morry.smulevitz@walgreens.com
Investor Relations:
+1-847-315-2922
http://news.walgreens.com
@WalgreensNews
facebook.com/Walgreens
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom